ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies (LIBERTY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03096834
Recruitment Status : Recruiting
First Posted : March 30, 2017
Last Update Posted : June 28, 2018
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to determine if AMG 334 is effective in treating migraines in patients who have unsuccessfully failed other preventive migraine treatments.

Condition or disease Intervention/treatment Phase
Episodic Migraine Biological: Pre-Filled Syringe (PFS) Biological: Placebo Pre-Filled Syringe (PFS) Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 220 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A 12-week Double-blind, Randomized, Multicenter Study Comparing the Efficacy and Safety of Once Monthly Subcutaneous AMG 334 Against Placebo in Adult Episodic Migraine Patients Who Have Failed Prophylactic Migraine Treatments
Actual Study Start Date : March 20, 2017
Actual Primary Completion Date : January 18, 2018
Estimated Study Completion Date : January 19, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Migraine

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Placebo Comparator: Placebo
Matching placebo injection, subcutaneous
 Biological: Placebo Pre-Filled Syringe (PFS)
Subcutaneous injection of placebo
Experimental: AMG 334
AMG 334 injection, subcutaneous
 Biological: Pre-Filled Syringe (PFS)
subcutaneous injection of AMG 334


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Percentage of patients with a 50% response in the reduction of Monthly Migraine Days (MMD) [ Time Frame: The last month (Month 3) of the Double-Blind Treatment Epoch (DBTE) ]
    Assessed via patient report collected in the headache e-diary.


Secondary Outcome Measures :
  1. Change in the number of monthly migraine days (MMDs) from baseline to month 3 [ Time Frame: Baseline, the last month (Month 3) of the Double-Blind Treatment Epoch (DBTE) ]
  2. Change in the Migraine Physical Function Impact Diary (MPFID) "impact on everyday activities" domain score from baseline to month 3 [ Time Frame: Baseline, month 3 of the DBTE ]
  3. Change in the MPFID "physical impairment" domain score from baseline to month 3 [ Time Frame: Baseline, month 3 of the DBTE ]
  4. Change in the number of monthly acute migraine-specific medication treatment days [ Time Frame: Baseline, last month (Month 3) of the Double-Blind Treatment Epoch (DBTE) ]
  5. Percentage of patients with a 75% response [ Time Frame: Baseline, last month (Month 3) of the Double-Blind Treatment Epoch (DBTE) ]
    Assessed via patient report collected in the headache e-diary.

  6. Percentage of patients with a 100% response [ Time Frame: Baseline, last month (Month 3) of the Double-Blind Treatment Epoch (DBTE) ]
    Assessed via patient report collected in the headache e-diary.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Documented history of migraine in the 12 months prior to screen
  • 4-14 days per month of migraine symptoms
  • >=80% diary compliance during the Baseline period
  • Failure of previous migraine prophylactic treatments

Exclusion Criteria:

  • >50 years old at migraine onset
  • Pregnant or nursing
  • History of cluster or hemiplegic headache
  • Evidence of seizure or psychiatric disorder
  • Score of 19 or higher on BDI
  • Active chronic pain syndrome
  • Cardiac or hepatic disease
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03096834


Contacts
Contact: Novartis Pharmaceuticals +41613241111 novartis.email@novartis.com
Contact: Novartis Pharmaceuticals

  Show 71 Study Locations
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03096834     History of Changes
Other Study ID Numbers: CAMG334A2301
2016-002211-18 ( EudraCT Number )
First Posted: March 30, 2017    Key Record Dates
Last Update Posted: June 28, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Migraine
attack
headache
episodic
 aura
AMG 334
CGRP receptor agonist
erenumab

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
 Brain Diseases
Central Nervous System Diseases
Nervous System Diseases